Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials

Table 1: Systolic and Diastolic Blood Pressure (Expressed in mmHg) During the GUIDE Study

Evaluation Time	Study Treatment	Baseline Values^*		Delta at Each Time Point
Evaluation Time	Study Treatment	Systolic	Diastolic	Systolic	Diastolic
Baseline	Placebo (n=107)	136 (16)	78 (11)	-	-
Baseline	CGS (n=109)	134 (15)	79 (11)	-	-
Day 15	Placebo (n=104)	137 (16)	78 (11)	-2 (12)	-1 (9)
Day 15	CGS (n=105)	134 (15)	79 (11)	-3 (13)	-1 (8)
Month 1	Placebo (n=97)	136 (16)	78 (11)	-1 (13)	0 (10)
Month 1	CGS (n=97)	134 (16)	78 (12)	-2 (11)	-1 (8)
Month 3	Placebo (n=92)	137 (16)	78 (11)	-2 (15)	-1 (11)
Month 3	CGS (n=93)	134 (16)	78 (12)	-3 (13)	-2 (8)
Month 6	Placebo (n=77)	137 (16)	78 (11)	-7 (14)	-4 (10)
Month 6	CGS (n=85)	134 (16)	78 (12)	-5 (15)	-5 (10)

Values are expressed as mean (SD); p=not significant in all comparisons.

^* In this column, the average of absolute values at baseline for the patients still in study at each time point is given.

CGS=crystalline glucosamine sulfate.